Commentary: Psoriasis patients with a history of malignancy represent an important but overlooked study population

Dermatology Online Journal

Volumn 17, Issue 2, 2011, Pages 10-

  Persad, Paul ^a   Levender, Michelle M ^a   Feldman, Steven R ^a  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOSPORIN; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOMODULATING AGENT; METHOTREXATE; METHOXSALEN; RETINOID; TUMOR NECROSIS FACTOR ALPHA INHIBITOR; TUMOR NECROSIS FACTOR INHIBITOR;

ARTICLE; CANCER RISK; DRUG EFFECT; DRUG SAFETY; ENTERITIS; HUMAN; LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MALIGNANT NEOPLASTIC DISEASE; MEDICAL HISTORY; PSORIASIS; PUVA; RISK BENEFIT ANALYSIS; SYSTEMIC THERAPY;

HUMANS; NEOPLASMS; PSORIASIS; SAFETY;

EID: 79953048669     PISSN: 10872108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (8)

1. Menter A, Gottlieb A, Feldman SR, Van Voorhees AS, Leonardi CL, Gordon KB et al. Guidelines of care for the management of psoriasis and psoriatic arthritis: Section 1. Overview of psoriasis and guidelines of care for the treatment of psoriasis with biologics. J Am Acad Dermatol 2008; 58(5):826-850. [PubMed]
2. Stern RS, Zierler S, Parrish JA. Methotrexate used for psoriasis and the risk of noncutaneous or cutaneous malignancy. Cancer 1982; 50(5):869-872. [PubMed]
3. Cockburn IT, Krupp P. The risk of neoplasms in patients treated with cyclosporine A. J Autoimmun 1989; 2(5):723-731. [PubMed]
4. Kamel OW. Lymphomas during long-term methotrexate therapy. Arch Dermatol 1997; 133(7):903-904. [PubMed]
5. Dommasch E, Gelfand JM. Is there truly a risk of lymphoma from biologic therapies? Dermatol Ther 2009; 22(5):418-430. [PubMed]
6. Lakatos PL, Miheller P. Is There an Increased Risk of Lymphoma and Malignancies Under Anti-TNF Therapy in IBD? Curr Drug Targets 2009. [PubMed]
7. Strangfeld A, Hierse F, Rau R, Burmester GR, Krummel-Lorenz B, Demary W et al. Risk of incident or recurrent malignancies among patients with rheumatoid arthritis exposed to biologic therapy in the German biologics register RABBIT. Arthritis Res Ther 2010; 12(1):R5. [PubMed]
8. Dixon WG, Watson KD, Lunt M, Mercer LK, Hyrich KL, Symmons DP. Influence of anti-tumor necrosis factor therapy on cancer incidence in patients with rheumatoid arthritis who have had a prior malignancy: results from the British Society for Rheumatology Biologics Register. Arthritis Care Res (Hoboken) 2010; 62(6):755-763. [PubMed]